Publications by authors named "Henrik Sliwka"
Article Synopsis
- Severe congenital protein C deficiency (SCPCD) is a rare, serious condition that leads to life-threatening blood issues shortly after birth, requiring effective treatment options.
- A targeted literature review summarized findings from 18 publications, primarily case studies, about long-term use of protein C concentrate (Ceprotin and Protexel) in managing SCPCD.
- Treatment with protein C concentrate showed generally positive outcomes, such as preventing complications and healing skin lesions, though dosing varied and some adverse effects were noted in limited cases.
Ciltacabtagene autoleucel (cilta-cel) is a Chimeric antigen receptor T-cell therapy with the potential for long-term disease control in heavily pre-treated patients with relapsed/refractory multiple myeloma (RRMM). As cilta-cel was assessed in the single-arm CARTITUDE-1 clinical trial, we used an external cohort of patients from the Therapie Monitor registry fulfilling the CARTITUDE-1 inclusion criteria to evaluate the effectiveness of cilta-cel for overall survival (OS) and time to next treatment (TTNT) vs. real-world clinical practice.
View Article and Find Full Text PDF